Literature DB >> 23522976

Apoptosis and p53 are not involved in the anti-tumor efficacy of ¹²⁵I-labeled monoclonal antibodies targeting the cell membrane.

Salomé Paillas1, Vincent Boudousq, Bérengère Piron, Nathalie Kersual, Manuel Bardiès, Nicolas Chouin, Caroline Bascoul-Mollevi, François-Xavier Arnaud, André Pèlegrin, Isabelle Navarro-Teulon, Jean-Pierre Pouget.   

Abstract

INTRODUCTION: (125)I-labeled monoclonal antibodies ((125)I-mAbs) can efficiently treat small solid tumors. Here, we investigated the role of apoptosis, autophagy and mitotic catastrophe in (125)I-mAb toxicity in p53(-/-) and p53(+/+) cancer cells.
METHODS: We exposed p53(-/-) and p53(+/+) HCT116 cells to increasing activities of internalizing (cytoplasmic location) anti-HER1 (125)I-mAbs, or non-internalizing (cell surface location) anti-CEA (125)I-mAbs. For each targeting model we established the relationship between survival and mean nucleus absorbed dose using the MIRD formalism.
RESULTS: In both p53(-/-) and p53(+/+) HCT116 cells, anti-CEA (125)I-mAbs were more cytotoxic per Gy than anti-HER1 (125)I-mAbs. Sensitivity to anti-CEA (125)I-mAbs was p53-independent, while sensitivity to anti-HER1 (125)I-mAbs was higher in p53(-/-) HCT 116 cells, suggesting that they act through different signaling pathways. Apoptosis was only induced in p53(+/+) HCT116 cells and could not explain cell membrane radiation sensitivity. Inhibition of autophagy did not modify the cell response to (125)I-mAbs. By contrast, mitotic death was similarly induced in both p53(-/-) and p53(+/+) HCT116 cells by the two types of (125)I-mAbs. We also showed using medium transfer experiments that γ-H2AX foci were produced in bystander cells.
CONCLUSION: Cell membrane sensitivity to (125)I-mAbs is not mediated by apoptosis and is p53-independent. Bystander effects-mediated mitotic death could be involved in the efficacy of (125)I-mAbs binding cell surface receptors.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23522976     DOI: 10.1016/j.nucmedbio.2013.02.001

Source DB:  PubMed          Journal:  Nucl Med Biol        ISSN: 0969-8051            Impact factor:   2.408


  9 in total

1.  Anti-L1CAM radioimmunotherapy is more effective with the radiolanthanide terbium-161 compared to lutetium-177 in an ovarian cancer model.

Authors:  Jürgen Grünberg; Dennis Lindenblatt; Holger Dorrer; Susan Cohrs; Konstantin Zhernosekov; Ulli Köster; Andreas Türler; Eliane Fischer; Roger Schibli
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-05-24       Impact factor: 9.236

Review 2.  Targeted and Off-Target (Bystander and Abscopal) Effects of Radiation Therapy: Redox Mechanisms and Risk/Benefit Analysis.

Authors:  Jean-Pierre Pouget; Alexandros G Georgakilas; Jean-Luc Ravanat
Journal:  Antioxid Redox Signal       Date:  2018-03-22       Impact factor: 8.401

Review 3.  The potential and hurdles of targeted alpha therapy - clinical trials and beyond.

Authors:  Jörgen Elgqvist; Sofia Frost; Jean-Pierre Pouget; Per Albertsson
Journal:  Front Oncol       Date:  2014-01-14       Impact factor: 6.244

Review 4.  Introduction to radiobiology of targeted radionuclide therapy.

Authors:  Jean-Pierre Pouget; Catherine Lozza; Emmanuel Deshayes; Vincent Boudousq; Isabelle Navarro-Teulon
Journal:  Front Med (Lausanne)       Date:  2015-03-17

5.  Beta emitters rhenium-188 and lutetium-177 are equally effective in radioimmunotherapy of HPV-positive experimental cervical cancer.

Authors:  Rebecca Phaeton; Zewei Jiang; Ekaterina Revskaya; Darrell R Fisher; Gary L Goldberg; Ekaterina Dadachova
Journal:  Cancer Med       Date:  2015-12-02       Impact factor: 4.452

6.  Targeted Radionuclide Therapy Using Auger Electron Emitters: The Quest for the Right Vector and the Right Radionuclide.

Authors:  Malick Bio Idrissou; Alexandre Pichard; Bryan Tee; Tibor Kibedi; Sophie Poty; Jean-Pierre Pouget
Journal:  Pharmaceutics       Date:  2021-06-29       Impact factor: 6.321

7.  Influence of P53 on the radiotherapy response of hepatocellular carcinoma.

Authors:  Ana R Gomes; Ana M Abrantes; Ana F Brito; Mafalda Laranjo; João E Casalta-Lopes; Ana C Gonçalves; Ana B Sarmento-Ribeiro; Maria F Botelho; José G Tralhão
Journal:  Clin Mol Hepatol       Date:  2015-09-30

8.  What is the Role of the Bystander Response in Radionuclide Therapies?

Authors:  Darren Brady; Joe M O'Sullivan; Kevin M Prise
Journal:  Front Oncol       Date:  2013-08-19       Impact factor: 6.244

9.  Localized Irradiation of Cell Membrane by Auger Electrons Is Cytotoxic Through Oxidative Stress-Mediated Nontargeted Effects.

Authors:  Salomé Paillas; Riad Ladjohounlou; Catherine Lozza; Alexandre Pichard; Vincent Boudousq; Marta Jarlier; Samuel Sevestre; Marion Le Blay; Emmanuel Deshayes; Jane Sosabowski; Thierry Chardès; Isabelle Navarro-Teulon; Robert J Mairs; Jean-Pierre Pouget
Journal:  Antioxid Redox Signal       Date:  2016-07-05       Impact factor: 8.401

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.